Are you Dr. Schalper?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
20 York St
New Haven, CT 06510Phone+1 203-688-4242
Summary
- Dr. Kurt Schalper, MD is a pathologist in New Haven, Connecticut. He is currently licensed to practice medicine in Connecticut.
Certifications & Licensure
CT State Medical License 2017 - Present
Publications & Presentations
PubMed
- IL-4 mediated TAP2 downregulation is a dominant and reversible mechanism of immune evasion and immunotherapy resistance in non-small cell lung cancer.Kishu Ranjan, Barani Kumar Rajendran, Imad Ud Deen, Adrien Costantini, Miguel Lopez de Rodas
Molecular Cancer. 2025-03-17 - 1 citationsAuthor Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun
Nature. 2025-03-01 - 3 citationsBiological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach.Miguel Lopez de Rodas, Maria Villalba-Esparza, Miguel F Sanmamed, Lieping Chen, David L Rimm
Nature Reviews. Clinical Oncology. 2025-03-01
Press Mentions
Journal Honors Deborah Blythe Doroshow, MD, PhD, as Recipient of the 2019 Journal of Clinical Oncology Young Investigator AwardAugust 1st, 2019
Grant Support
- Understanding the role and clinical potential of dominant immune suppressive myeloid-cell responses in human cancerYALE UNIVERSITY2021–2026
- Understanding the role and clinical potential of dominant immune suppressive myeloid-cell responses in human cancerYALE UNIVERSITY2021–2026
- Quantitative and Spatially-Resolved Analysis of the Tumor Immune Contexture for Optimal Diagnosis and Treatment of Lung CancerYALE UNIVERSITY2020–2025
- Quantitative and Spatially-Resolved Analysis of the Tumor Immune Contexture for Optimal Diagnosis and Treatment of Lung CancerYALE UNIVERSITY2020–2025
- Quantitative and Spatially-Resolved Analysis of the Tumor Immune Contexture for Optimal Diagnosis and Treatment of Lung CancerYALE UNIVERSITY2020–2025
- CHIRP Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung CancersEMORY UNIVERSITY2018–2024
